- Home
- ADXN vs BGLC Comparison
ADXN vs BGLC Comparison
Compare ADXN & BGLC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADXN
- BGLC
- Stock Information
- Founded
- ADXN 2002
- BGLC 2017
- Country
- ADXN Switzerland
- BGLC Malaysia
- Employees
- ADXN N/A
- BGLC N/A
- Industry
- ADXN Biotechnology: Pharmaceutical Preparations
- BGLC Medical Specialities
- Sector
- ADXN Health Care
- BGLC Health Care
- Exchange
- ADXN Nasdaq
- BGLC Nasdaq
- Market Cap
- ADXN 11.3M
- BGLC 7.6M
- IPO Year
- ADXN N/A
- BGLC N/A
- Fundamental
- Price
- ADXN $10.30
- BGLC $0.37
- Analyst Decision
- ADXN Strong Buy
- BGLC
- Analyst Count
- ADXN 1
- BGLC 0
- Target Price
- ADXN $30.00
- BGLC N/A
- AVG Volume (30 Days)
- ADXN 22.8K
- BGLC 117.9K
- Earning Date
- ADXN 11-11-2024
- BGLC 11-20-2024
- Dividend Yield
- ADXN N/A
- BGLC N/A
- EPS Growth
- ADXN N/A
- BGLC N/A
- EPS
- ADXN 0.05
- BGLC N/A
- Revenue
- ADXN $960,641.00
- BGLC $9,183,168.00
- Revenue This Year
- ADXN N/A
- BGLC N/A
- Revenue Next Year
- ADXN N/A
- BGLC N/A
- P/E Ratio
- ADXN $1.75
- BGLC N/A
- Revenue Growth
- ADXN N/A
- BGLC N/A
- 52 Week Low
- ADXN $5.00
- BGLC $0.31
- 52 Week High
- ADXN $27.90
- BGLC $3.39
- Technical
- Relative Strength Index (RSI)
- ADXN 54.08
- BGLC 32.80
- Support Level
- ADXN $10.04
- BGLC $0.38
- Resistance Level
- ADXN $10.81
- BGLC $0.49
- Average True Range (ATR)
- ADXN 0.59
- BGLC 0.02
- MACD
- ADXN 0.04
- BGLC -0.01
- Stochastic Oscillator
- ADXN 70.88
- BGLC 5.94
About ADXN Addex Therapeutics Ltd
Addex Therapeutics Ltd is a clinical stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment which is the discovery, development and commercialization of small-molecule pharmaceutical products.
About BGLC BioNexus Gene Lab Corp Common stock
BioNexus Gene Lab Corp through its wholly owned subsidiary, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. In addition, the Company is in the business of developing and providing safe, effective, and non-invasive liquid biopsy tests for the early detection of biomarkers that it believes are linked to diseases to minimize treatment costs and improve patient management. Its non-invasive blood tests provide analysis of changes in RNA to detect the potential risk of 11 different diseases.